GlassScriptPhysician profile
Terrence M Feehery
NPI 1821060559
$5,538.70
in general payments reported to CMS, 2019-2025
42 companies · $68.93 in 2025
The $68.93 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,720 · 2020: $635 · 2021: $1,450 · 2022: $1,278 · 2023: $387 · 2025: $68.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.17 | 2019-2023 | |
| Novo Nordisk INC | $527.20 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $471.99 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $417.35 | 2019-2023 | Shingrix |
| Amarin Pharma, INC. | $379.96 | 2019-2022 | |
| Lilly USA, LLC | $321.58 | 2019-2022 | |
| Amgen INC. | $303.16 | 2019-2022 | |
| Pfizer INC. | $272.94 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $256.73 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.73 | 2020-2023 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $139.95 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.73 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $126.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $103.53 | 2019-2023 | |
| Upsher-Smith Laboratories LLC | $101.28 | 2021-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Feehery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.